Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Karen S.

Karen S. Century, Albany, CA US

Patent application numberDescriptionPublished
20080301836Selection of transcription factor variants - The invention relates to a method for selection of modified plant transcription factor polypeptides, polynucleotides that encode them, and methods of producing transgenic plants having advantageous properties, including increased biotic resistance and abiotic stress tolerance, as compared to wild-type or control plants. Without modifications, the transcription factor sequences, when overexpressed in plants, often produce adverse morphological and developmental effects. The disclosed method allows selection of modifications that mitigate these adverse morphological and developmental effects.12-04-2008
20080301840Conferring biotic and abiotic stress tolerance in plants - The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties, tolerance low nitrogen, cold and water deficit conditions, and resistance to disease, as compared to wild-type or other control plants.12-04-2008
20090138981Biotic and abiotic stress tolerance in plants - Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include, for example, salt, hyperosmotic stress, water deficit, heat, cold, drought, or low nutrient conditions.05-28-2009
20090151015DISEASE-INDUCIBLE PROMOTERS - Disease-inducible promoter sequences have been identified that may be used to produce transgenic plants that are both more resistant to disease than control plants, and are wild-type or nearly wild type in appearance. Any of these disease-inducible promoters may be incorporated into expression vectors that each comprise a defense response protein operably linked to the promoter. The expression vectors can be introduced into plants and the defense response protein then ectopically expressed. Transgenic plants transformed with many of these expression vectors have been shown to be more resistant to disease, in some cases, to more than one type of pathogen, and yet are similar to wild type plants in their morphology and development.06-11-2009
20090265807Polynucleotides and polypeptides in plants - The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed.10-22-2009
20090265813STRESS TOLERANCE IN PLANTS - Transcription factor polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these expression vectors have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include salt, hyperosmotic stress, heat, cold, drought, or low nitrogen conditions.10-22-2009
20100175145PLANT TRANSCRIPTIONAL REGULATORS - The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.07-08-2010
20110126326STRONG ACTIVATION DOMAIN - A new and strong transcriptional activation domain was identified from the 05-26-2011

Patent applications by Karen S. Century, Albany, CA US

Karen S. De Jongh, Seattle, WA US

Patent application numberDescriptionPublished
20080293122Method for Activating Prethrombin-1 - Methods for converting prethrombin-1 to thrombin are disclosed. An aqueous solution of prethrombin-1 is applied to oscutarin-C immobilized on a solid support so as to provide from 500 mg to 4000 mg of prethrombin-1 per mL of the solid support and a contact time between the prethrombin-1 and the oscutarin-C of from 1.8 to 3.5 minutes. The resulting active thrombin may be captured on an ion exchange chromatography medium or an affinity chromatography medium.11-27-2008

Patent applications by Karen S. De Jongh, Seattle, WA US

Karen S. Gushurst, West Lafayette, IN US

Patent application numberDescriptionPublished
20100174064FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.07-08-2010
20100239664FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.09-23-2010
20110105550FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.05-05-2011

Patent applications by Karen S. Gushurst, West Lafayette, IN US

Karen S. Slobod, Somerville, MA US

Patent application numberDescriptionPublished
20100098721METHODS AND COMPOSITIONS FOR PREPARING A UNIVERSAL INFLUENZA VACCINE - Compositions and methods for preventing and treating influenza virus infections are provided. Compositions include novel immunogenic compositions having at least one vector capable of expressing an antigenic component from four or more influenza viruses representative of the antigenic diversity of a target population of influenza virus strains. Compositions further include novel immunogenic compositions having at least four vectors, each vector capable of expressing a single antigenic component representative of the antigenic diversity of a target population of influenza virus strains. In other aspects of the invention, the immunogenic compositions also include one or more viral proteins (or antigenic portions thereof), or one or more live attenuated viruses, derived from the target population of influenza virus strains. The invention further provides methods for making a multi-valent influenza vaccine and methods for inducing an immune response in a subject against influenza viruses.04-22-2010